Oppenheimer Reiterates Outperform on Eiger BioPharmaceuticals (EIGR) Following AASLD

Oppenheimer reiterated an Outperform rating and $34.00 price target on Eiger BioPharmaceuticals (NASDAQ: EIGR) after attending AASLD. Oppenheimer detected a notable level of enthusiasm around new treatments in development for hepatitis D virus (HDV). EIGR is developing lonafarnib and PEG-IFNλ for the treatment of HDV, and based on the data presented at AASLD, we believe these could become the first FDA-approved therapies for HDV.

Analyst Jay Olson commented, "We attended AASLD, and despite the almost overwhelming attention to NASH, we detected a notable level of enthusiasm around new treatments in development for hepatitis D virus (HDV). Most importantly, several abstracts featuring interim data from EIGR's LOWR HDV program were presented. This note summarizes our key takeaways from these presentations. Please see inside for complete details."

For an analyst ratings summary and ratings history on Eiger BioPharma click here. For more ratings news on Eiger BioPharma click here.

Shares of Eiger BioPharma closed at $12.45 yesterday.

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• Keurig Dr Pepper (KDP) PT Raised to $39 at Jefferies
• Sage Therapeutics (SAGE) PT Lowered to $18 at Truist Securities